Therefore, in NSCLC patients with initial BM, subsequent treatment directed by driver gene mutation after first line EGFR-TKI failure might provide more therapeutic effect and survival benefit than conventional chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.